The Europe AI In Drug Repurposing Market would witness market growth of 19.3% CAGR during the forecast period (2025-2032).
The Germany market dominated the Europe AI In Drug Repurposing Market by Country in 2024, and would continue to be a dominant market till 2032; thereby, achieving a market value of $269.5 million by 2032. The UK market is exhibiting a CAGR of 18.3% during (2025 - 2032). Additionally, The France market would experience a CAGR of 20.1% during (2025 - 2032). The Germany and UK led the Europe AI In Drug Repurposing Market by Country with a market share of 25% and 20.7% in 2024. The Italy market is expected to witness a CAGR of 20.2% during throughout the forecast period.
Europe's strong history in life sciences, biomedical research, and strict rules has made it a good place for artificial intelligence to be used in drug repurposing. The field started with academic and translational research centers, but it has grown as computing power and access to biomedical datasets have improved, allowing AI to make repurposing efforts bigger. The market is moving from separate projects to an integrated ecosystem that values data sharing, openness, and precision-driven innovation. This is happening thanks to pan-European initiatives, open data platforms, and regulatory engagement.
Federated learning is being used more and more to protect privacy under GDPR. EU-funded consortia are also helping public and private organizations work together more. There is also a growing focus on making models easier to understand and making sure they follow the rules. Top companies put explainability, interoperability, and compliance first when they spend money on federated data networks and AI platforms that can grow and change. Competition is still changing, and players who know about regulations, can work together, and have proven results in translation have the upper hand. So, the AI market for drug repurposing in Europe is becoming a coordinated and trusted system that balances new ideas with strict rules and ethics.
Based on Component, the market is segmented into Software & Platform, and Services. The Software & Platform market segment dominated the Germany AI In Drug Repurposing Market by Component is expected to grow at a CAGR of 17.5 % during the forecast period thereby continuing its dominance until 2032. Also, The Services market is anticipated to grow as a CAGR of 18.5 % during the forecast period during (2025 - 2032).
Based on Application, the market is segmented into Oncology, Neurology, Infectious Diseases, Rare & Orphan Diseases, Cardiology, and Other Application. Among various UK AI In Drug Repurposing Market by Application; The Oncology market achieved a market size of USD $21 Million in 2024 and is expected to grow at a CAGR of 16.8 % during the forecast period. The Cardiology market is predicted to experience a CAGR of 19.4% throughout the forecast period from (2025 - 2032).
Free Valuable Insights: The Global AI In Drug Repurposing Market will Hit USD 4.11 Billion by 2032, at a CAGR of 19.7%
Germany is a top place for AI-driven drug repurposing because it has a strong research and development ecosystem, a well-established pharmaceutical industry, and forward-thinking digital health policies. Strong collaboration between academia and industry, a lot of public funding, and strict regulatory oversight that makes sure AI models meet high validation standards are all good things for the country. Some important trends are the use of AI to look at genomics and clinical datasets, the rise of federated learning, and a growing interest in rare disease and precision medicine applications. Bayer and Merck KGaA are two of the biggest companies in the market, along with new startups. The market is competitive but open. Germany's well-developed infrastructure and strict rules make it the best place in Europe to advance AI in drug repurposing.
By Component
By Technology
By End Use
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 